Skip to main
AUTL

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics is a biopharmaceutical company with a promising pipeline of therapies, including Obe-cel and Aucatzyl, that target various diseases such as B-ALL, autoimmune diseases, progressive MS, and lupus nephritis. The company has shown positive results in trials for pediatric patients and is investing in improvements to address manufacturing challenges. While there are risks associated with investing in a development-stage company, Autolus has the potential to provide new and improved treatments for a range of diseases and has a potential revenue stream from Aucatzyl with an estimated annual price of $525,000.

Bears say

Autolus Therapeutics is facing major risks in the commercialization of their CAR-T therapies, with potential concerns regarding safety and long-term efficacy as most patients eventually experience relapse. In addition, the company is heavily reliant on their lead asset, Aucatzyl, for future revenue as their pipeline-in-a-product strategy for B-cell depleting disorders may not yield the desired results. Furthermore, Autolus is facing stiff competition in the CAR-T market and may struggle to capture market share, resulting in potentially low sales and financial performance in the near term.

Autolus Therapeutics (AUTL) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Buy based on their latest research and market trends.

According to 4 analysts, Autolus Therapeutics (AUTL) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.